Zealand Pharma A/S
ZEALDrugs in Pipeline
9
Phase 3 Programs
3
Upcoming Catalysts
4
Next Catalyst
Apr 2, 2026
5dMarket Overview
Stock performance and key metrics
4 upcoming, 0 past
Petrelintide Phase 2 Results Expected
Primary completion for Petrelintide trial (NCT06926842) in Overweight
Source3 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
GlucaGen
Hypoglycemia
Glepaglutide
Short Bowel Syndrome
dasiglucagon
Hypoglycemia
Insulin Lispro
Diabetes Mellitus, Type 1
ZP4207
Hypoglycemia
ZP4207(dasiglucagon) glucagon analogue
Diabetes Mellitus Type 1
ZP1848
Short Bowel Syndrome
Petrelintide
Obesity
danegaptide
Focus of Study is STEMI
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GlucaGen | Phase 3 | Hypoglycemia | - | - |
Glepaglutide | Phase 3 | Short Bowel Syndrome | - | - |
dasiglucagon | Phase 3 | Hypoglycemia | - | - |
Insulin Lispro | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
ZP4207 | Phase 2 | Hypoglycemia | - | - |
ZP4207(dasiglucagon) glucagon analogue | Phase 2 | Diabetes Mellitus Type 1 | - | - |
ZP1848 | Phase 2 | Short Bowel Syndrome | - | - |
Petrelintide | Phase 2 | Obesity | - | - |
danegaptide | Phase 2 | Focus of Study is STEMI | - | - |